Skip to main content
TipRanks
Go Ultimate75% OFF

FALCO HOLDINGS Co., Ltd (4671) AI Stock Analysis

1 Followers
JP:4671

FALCO HOLDINGS Co., Ltd

(TSE/TYO:4671)

Select Model
Rating:72Outperform
Price Target:JPY 3,146.00â–²(15.20% Upside)
Action:reiterated
Date:08/17/26

The stock scores 72, reflecting a solid financial foundation with a strong balance sheet and healthy cash flows, offset by some margin pressure. The technical picture shows a bullish trend but is overbought, suggesting caution in the short term. Valuation appears attractive with a reasonable P/E and high dividend yield. Overall, the company is well-positioned in the Medical Diagnostics & Research industry.

Positive Factors
Low Financial LeverageVery low and improving leverage gives FALCO substantial financial flexibility. The company is less dependent on borrowing, reducing solvency risk and preserving capacity to fund operations, investment, or shareholder returns through changing conditions.
Negative Factors
Margin CompressionAlthough profitability remains positive, lower operating and net margins indicate that earnings power is weaker than at the 2022 peak. Persistent compression could limit profit growth even if revenue continues recovering.

FALCO HOLDINGS Co., Ltd (4671) vs. iShares MSCI Japan ETF (EWJ)

-5%0%5%10%15%20%25%30%JP:4671+13.13%EWJ+18.48%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
JPY 26.96B
Dividend Yield
4.63%
Average Volume (3M)
18.29K
Price to Earnings (P/E)
12.6
Beta (1Y)
0.53
Revenue Growth
1.19%
EPS Growth
16.02%
Country
Japan
Employees
1,037
Sector
General
Sector Strength
55
Industry
Medical - Diagnostics & Research

FALCO HOLDINGS Co., Ltd Business Overview & Revenue Model

Company Description

FALCO HOLDINGS Co., Ltd., a medical services enterprise established in 1962 and headquartered in Kyoto, Japan, primarily delivers clinical diagnostic testing and pharmaceutical dispensing solutions. The company serves medical institutions and various...

How the Company Makes Money

FALCO HOLDINGS generates revenue mainly by providing clinical laboratory testing services to healthcare providers. In this model, medical institutions (e.g., clinics and hospitals) send patient specimens to the company’s laboratories for analysis; th...

FALCO HOLDINGS Co., Ltd Financial Statement Overview

Summary

Revenue growth rebounded (12.6% latest year) and gross margins improved, but operating margin declined indicating expense pressure. Balance sheet is strong with low debt (debt-to-equity 0.05) and growing equity. Cash flow generation is healthy. Overall solid but with some income statement weakness.

Income Statement

58Neutral

Balance Sheet

85Very Positive

Cash Flow

72Positive
Financial statement breakdown
BreakdownTTMMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue44.10B43.58B43.31B43.01B46.91B50.01B
Gross Profit14.29B13.81B13.35B12.92B14.64B17.32B
EBITDA4.02B3.56B3.72B3.56B4.75B6.55B
Net Income2.17B2.02B1.92B1.67B2.26B3.53B
Balance Sheet
Total Assets37.04B36.86B36.02B36.42B38.89B40.26B
Cash, Cash Equivalents and Short-Term Investments9.25B9.27B9.42B10.06B12.60B10.64B
Total Debt939.00M1.25B1.44B817.00M2.80B4.07B
Total Liabilities11.25B10.99B10.76B10.40B12.30B16.77B
Stockholders Equity25.79B25.87B25.25B26.03B26.59B23.48B
Cash Flow
Free Cash Flow01.54B1.54B2.19B708.00M1.94B
Operating Cash Flow02.88B2.62B3.43B2.09B4.13B
Investing Cash Flow0-2.03B-1.18B-1.45B322.00M-2.69B
Financing Cash Flow0-2.00B-2.08B-4.53B-448.00M-2.41B

FALCO HOLDINGS Co., Ltd Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

JP:4671 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
JP:4671JP:467172OutperformJPY 26.84B12.56―4.63%1.19%16.02%
JP:4694JP:469470OutperformJPY 148.09B19.515.92%3.22%3.54%10.43%
JP:4538JP:453864NeutralJPY 19.31B8.49―4.09%2.29%―
JP:4579JP:457964NeutralJPY 16.82B44.72――31.84%―
JP:2395JP:239559NeutralJPY 51.58B8.90―4.04%1.89%22.53%
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
JP:4563JP:456342NeutralJPY 11.13B-1.91-558.92%―19.67%84.06%

* General Sector Average

Performance Comparison

-50%0%50%100%150%JP:4671JP:4563JP:4694JP:2395JP:4538JP:4579Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
JP:4671 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
JP:4671FALCO HOLDINGS Co., Ltd2731.00301.6612.42%
JP:4563AnGes 27.00-47.00-63.51%
JP:4694BML 3960.00417.9611.80%
JP:2395Shin Nippon Biomedical Laboratories, Ltd.1239.00-324.11-20.73%
JP:4538Fuso Pharmaceutical Industries,Ltd.2201.00128.936.22%
JP:4579RaQualia Pharma Inc.646.0083.0014.74%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Aug 17, 2026